RRC ID 72619
Author Nakagawa S, Matsuoka Y, Ichihara H, Yoshida H, Yoshida K, Ueoka R.
Title Therapeutic effects of autologous lymphocytes activated with trastuzumab for xenograft mouse models of human breast cancer.
Journal Biol Pharm Bull
Abstract Trastuzumab (TTZ) is molecular targeted drug used for metastatic breast cancer patients overexpressing human epidermal growth factor receptor 2 (HER2). Therapeutic effects of lymphocytes activated with TTZ (TTZ-LAK) using xenograft mouse models of human breast cancer (MDA-MB-453) cells were examined in vivo. Remarkable reduction of tumor volume in a xenograft mouse models intravenously treated with TTZ-LAK cells after the subcutaneously inoculated of MDA-MB-453 cells was verified in vivo. The migration of TTZ-LAK cells in tumor of mouse models subcutaneously inoculated MDA-MB-453 cells was observed on the basis of histological analysis using immunostaining with CD-3. Induction of apoptosis in tumor of xenograft mice treated with TTZ-LAK cells was observed in micrographs using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) method. It was noteworthy that the therapeutic effects of TTZ-LAK cells along with apoptosis were obtained for xenograft mouse models of human breast tumor in vivo.
Volume 36(5)
Pages 861-5
Published 2013-1-1
DOI 10.1248/bpb.b12-01084
PII DN/JST.JSTAGE/bpb/b12-01084
PMID 23649343
MeSH Animals Antibodies, Monoclonal, Humanized / administration & dosage* Antineoplastic Agents / administration & dosage* Apoptosis / drug effects Breast Neoplasms / pathology Breast Neoplasms / therapy* Cell Line, Tumor Female Humans Immunotherapy, Adoptive* Killer Cells, Lymphokine-Activated* Lymphocyte Activation Mice Mice, Inbred BALB C Trastuzumab Tumor Burden / drug effects Xenograft Model Antitumor Assays
Human and Animal Cells MDA-MB-453(RCB1192)